PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Mycophenolate mofetil - Gastroenterology indications

PAD Profile : Mycophenolate mofetil - Gastroenterology indications

Keywords :
Crohn's disease, ulcerative colitis, mycophenolic sodium, mycophenolic acid, inflammatory bowel disease, IBD, RMOC, National shared care
Brand Names Include :
Arzip, CellCept, Myfortic, Myfenax, Ceptava

Traffic Light Status

Status 1 of 1.

Status :
Amber
Important
Formulations :
  • Capsules
  • Oral suspension
  • Tablets
Important Information :
Prescribe generically (except in transplant indications)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
07 December 2022
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) has agreed the National Shared Care Protocol (with local adaptations) for mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More